ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Yellow Fever Vaccine

Also written as “Yellow fever vaccine (produced on serum-free Vero cells)”, “Yellow fever vaccine (live)” and “Yellow Fever vaccine”.

Its studies are mostly in Yellow Fever · Measles · Severe Dengue · Malaria · Streptococcal Infections, led by 4 companies.

Drug pageYellow Fever Vaccine: every studyAll 25 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Sep 7, 201111 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi62 open or runningphase 3since Sep 7, 2011Sep 21, 2009none ahead
GlaxoSmithKlineits history only30 open or runningphase 3since Feb 23, 2016Dec 2, 2010none ahead
Novartisits history only10 open or runningphase 3since Nov 3, 2011Nov 3, 2011none ahead
Sinopharmits history only10 open or runningphase 3since Apr 30, 2024Apr 30, 2024none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sanofi only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 21, 2009First study: phase 2 study in Encephalitis, JapaneseFirst studyNCT00982137 · 108 enrolled · Australia
  2. Sep 7, 2011Phase 3 study in DengueNCT01436396 · 792 enrolled · Colombia, Peru
  3. Jun 25, 2021Phase 2 study in Yellow FeverNCT04942210 · 568 enrolled · United States
  4. Aug 17, 2021Phase 2 study in Yellow FeverNCT05011123 · 690 enrolled · Finland, France, Germany and more
  5. May 23, 2025Phase 3 study in Yellow FeverNCT07002060 · 640 enrolled · United States
  6. Oct 27, 2025Phase 3 study in Yellow FeverNCT07222059 · 254 enrolled · Japan

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

Studies

All 6 Sanofi leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07222059Yellow Fever · Japan3CompletedDec 25, 2025254
NCT07002060Yellow Fever · United States3CompletedJan 20, 2026640
NCT05011123Yellow Fever · Finland, France, Germany and more2Active, not recruitingMay 23, 2022690
NCT04942210Yellow Fever · United States2Active, not recruitingJun 24, 2022568
NCT01436396Dengue · Colombia, Peru3CompletedSep 2013792
NCT00982137Encephalitis, Japanese · Australia2CompletedApr 2005108

How it is read

Names in the registry

  • “Yellow fever vaccine (produced on serum-free Vero cells)”, 2 entries
  • “Yellow fever vaccine (live)”, 2 entries
  • “Yellow Fever Vaccine”, 2 entries
  • “Yellow Fever vaccine”, 1 entry
  • “YF vaccine (live)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.